Obesity is a chronic condition rising in the UK and worldwide, increasing risks of type 2 diabetes, heart disease, and reduced quality of life. As treatment options expand, patients often ask, “Is surgery still the best option, or can weight-loss medications match its results?”
A study presented at the ASMBS Annual Meeting in June 2024 reviewed global evidence comparing three common approaches: lifestyle changes, GLP-1 receptor agonist drugs (like semaglutide and tirzepatide), and bariatric surgery. While mostly based on data outside the UK, the findings offer insights into long-term outcomes.
Key Findings
- Lifestyle interventions (diet, exercise) yielded an average weight loss of 7.4%, but most of this was regained within roughly four years.
- GLP‑1 medications showed impressive short-term results—10.6% weight loss in five months with semaglutide and 21.1% in nine months with tirzepatide. However, after stopping medication, about half the weight was typically regained within a year.
- Bariatric surgery (gastric bypass, sleeve gastrectomy) delivered the most substantial and durable results—31.9% and 29.5% weight loss at one year, with approximately 25% weight still lost even ten years post-surgery.
What It Means
GLP‑1 drugs clearly advanced obesity treatment and are effective while taken. But their benefits largely depend on continued use. By contrast, surgery often provides more permanent changes, both metabolic and behavioural, from a one-time intervention, supported by ongoing care. These weight loss procedures alter hunger regulation and digestion, enabling sustained weight maintenance without lifelong medication.
That said, bariatric surgery is not without challenges. It requires ongoing commitment, follow-up care, nutritional guidance, and monitoring. It isn’t a quick fix, but for individuals with severe or complex obesity, or who haven’t succeeded with other methods, it can be one of the most effective long-term treatments.
Relevance for UK Patients
GLP‑1 medications are becoming more accessible in the UK, though NHS availability varies and long-term use is typically needed. Bariatric surgery remains a one-time option via NHS pathways for eligible patients or privately through specialist weight loss providers like Phoenix Health. Although often considered a last resort, international data—including the ASMBS analysis—shows that when paired with proper support, surgery can deliver durable, long-term success for those with more severe obesity.
In practice, UK clinicians observe similar results: surgery often leads to more sustained outcomes than medication alone. However, every individual is different. The choice between surgery, medication, or a combination should be made in close consultation with a healthcare team that understands your medical history, goals, and circumstances.
Bottom line: There’s no one-size-fits-all solution, only a range of safe, effective options that, with the right guidance and support, can lead to meaningful, lasting success.
Medically Reviewed by Mr. Qutayba Almerie, MD, MSc, FRCS
Consultant Upper GI & Bariatric Surgeon, Medical Director at Phoenix Health.
Reference:
